Prevention, Combination Therapy, and Comparative Effectiveness Research RFP
Funds human studies testing drugs, supplements, or devices to prevent or reduce Alzheimer’s and dementia risk, emphasizing strong scientific rationale and biomarker outcomes.
Funder: Alzheimer's Drug Discovery Foundation
Due Dates: September 14, 2026: Letter of Intent deadline (must be received by 5:00 pm ET)
Funding Amounts: Up to $5,000,000 for clinical trials; multi-year awards; milestone-based payments; direct costs only.
Summary: Funds human studies on precision prevention, combination therapies, and comparative effectiveness to reduce Alzheimer’s and dementia risk, emphasizing strong scientific rationale and biomarker outcomes.
Key Information: Open to global academic, nonprofit, and biotech applicants; only one LOI per cycle per applicant.
Description
This funding opportunity supports human research focused on precision prevention, combination therapies, and comparative effectiveness to reduce the risk of Alzheimer’s disease and other dementias. The Alzheimer’s Drug Discovery Foundation (ADDF) seeks projects investigating targeted interventions—such as novel or repurposed drugs, supplements, or devices—that modify dementia risk factors or mechanisms related to the biology of aging. Priority is given to studies with robust scientific rationale, biomarker-based outcomes, and intellectual property potential. Eligible research includes randomized controlled trials, epidemiological studies, and long-term follow-up of completed prevention trials, provided the focus remains on human populations at risk for dementia based on genetic, biomarker, or clinical risk factors.
